A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Open Access
- 20 May 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Abstract
Small cell lung cancer (SCLC) is the most aggressive neuroendocrine phenotype of the deadliest human lung cancers. However the therapeutic landscape for SCLC has not changed in over 30 years. Effective treatment and prognosis are needed to combat this aggressive cancer. Herein we report that Ser/Arg repetitive matrix 4 (SRRM4), a splicing activator, is abnormally expressed at high levels in SCLC and thus is a potential therapeutic target. We screened an effective gapmer antisense oligonucleotide (gASO) targeting SRRM4 in vitro which led to cell death of SCLC. Our gASO, which is stabilized by containing artificial nucleotides, effectively represses SRRM4 mRNA. We found that our gASO repressed SRRM4 synthesis leading to a dramatic tumor reduction in a lung cancer mouse model. We also analyzed miRNA microarray and found that the miR-4516 is abnormally increased in exosomes in the blood of SCLC patients. Treating with gASO suppressed tumors in the SCLC model mouse concurrently reduced plasma miR-4516. In conclusion this study reports that administration of an SRRM4-targeted gASO coupled with a novel miRNA diagnostic methodology represents a potential breakthrough in the therapeutic treatment of high mortality SCLC.Keywords
Funding Information
- Japan Agency for Medical Research and Development (DNW-14028)
This publication has 44 references indexed in Scilit:
- Cross-Regulation between an Alternative Splicing Activator and a Transcription Repressor Controls NeurogenesisMolecular Cell, 2011
- Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancerOncogene, 2010
- The Transcription Factor REST Is Lost in Aggressive Breast CancerPLOS Genetics, 2010
- Alternative Splicing in Lung CancerJournal of Thoracic Oncology, 2009
- Transcriptional Regulation: Cancer, Neurons and the RESTCurrent Biology, 2005
- A Genetic Screen for Candidate Tumor Suppressors Identifies RESTCell, 2005
- Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cellsOncogene, 2003
- Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genesNature Genetics, 2003
- LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognitionChemical Communications, 1998
- Lung carcinoma and malignant mesothelioma in patients exposed to thorotrast: Incidence, histology and p53 statusInternational Journal of Cancer, 1995